Peggs K S, Quezada S A, Allison J P
Department of Haematology, UCL Cancer Institute, Paul O'Gorman Building, University College London, London, UK.
Clin Exp Immunol. 2009 Jul;157(1):9-19. doi: 10.1111/j.1365-2249.2009.03912.x. Epub 2009 Feb 18.
The generation and maintenance of immune responses are controlled by both co-stimulatory and co-inhibitory signalling through T cell co-receptors, many of which belong to the immunoglobulin-like superfamily or the tumour necrosis factor receptor superfamily. Agonistic or antagonistic monoclonal antibodies targeting these co-receptors have the potential to enhance immunity. Furthermore, their activity on the immunosuppressive regulatory T cell populations which are prevalent within many tumours provides an additional rationale for their use as anti-cancer therapies. This review summarizes the interactions between cancer and the immune system, highlighting the ways in which these new classes of immunostimulatory antibodies might enhance anti-tumour immunity and summarizing early clinical experience with their use.
免疫反应的产生和维持由通过T细胞共受体的共刺激和共抑制信号控制，其中许多共受体属于免疫球蛋白样超家族或肿瘤坏死因子受体超家族。靶向这些共受体的激动性或拮抗性单克隆抗体有可能增强免疫力。此外，它们对许多肿瘤中普遍存在的免疫抑制调节性T细胞群体的作用为其作为抗癌疗法的应用提供了额外的理论依据。本综述总结了癌症与免疫系统之间的相互作用，强调了这些新型免疫刺激抗体增强抗肿瘤免疫力的方式，并总结了其使用的早期临床经验。
